Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Eluting Stents (DES) Clear all
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

NCT00781573
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 23, 2026, 9:59 PM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT02389946
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES, Xience DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
55
States / cities
Fairhope, Alabama • Concord, California • La Mesa, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

NCT02073565
View directory record Official record
Conditions
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions
OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
Device
Lead sponsor
OrbusNeich
Industry
Eligibility
20 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
17
States / cities
Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Jul 23, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

NCT00910299
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Jul 23, 2026, 9:59 PM EDT
Completed No phase listed Observational

An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).

NCT00489320
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis, Atherosclerosis
Interventions
Cypher Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
7,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Study of BioNIR Drug Eluting Stent System in Coronary Stenosis

NCT01995487
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
BioNIR, Resolute
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Jul 23, 2026, 9:59 PM EDT
Withdrawn No phase listed Observational

Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)

NCT01003795
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 23, 2026, 9:59 PM EDT
Terminated Not applicable Interventional

Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents

NCT03671655
View directory record Official record
Conditions
Peripheral Vascular Diseases, Chronic Total Occlusion of Artery of the Extremities
Interventions
Drug-eluting stent, Bare metal stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 23, 2026, 9:59 PM EDT
Terminated Not applicable Interventional

Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)

NCT01962740
View directory record Official record
Conditions
Drug Eluting Stents (DES), Percutaneous Coronary Intervention (PCI), Uncovered and Malapposed Stent Struts, Optical Coherence Tomography (OCT)
Interventions
Drug-eluting stent implantation
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

Abbott Next Generation Drug Eluting Stent 48mm Study

NCT04282148
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ABT NG DES 48 EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

NCT01500434
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
21
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Jul 23, 2026, 9:59 PM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT04175626
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Fairhope, Alabama • Concord, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 9:59 PM EDT
Completed No phase listed Observational

Xience V at Wake Forest University Baptist Medical Center (WFUBMC)

NCT00937573
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Stents
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

TAXUS PERSEUS Workhorse

NCT00484315
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
82
States / cities
Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Not applicable Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 9:59 PM EDT
Completed Phase 3 Interventional Results available

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

NCT03551496
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
Combination Product · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
26
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 23, 2026, 9:59 PM EDT